Live feed06:59:00·108dPRReleasevia QuantisnowBristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple MyelomaByQuantisnow·Wall Street's wire, on your screen.BMY· Bristol-Myers Squibb CompanyHealth Care
